## Multi-omics highlights ABO plasma protein as a causal risk factor for COVID-19

*Human Genetics*

Ana I. Hernández Cordero1, Xuan Li1, Stephen Milne1,2,3, Chen Xi Yang1, Yohan Bossé4, Philippe Joubert4, Wim Timens5,Maarten van den Berge6, David Nickle7, Ke Hao8, Don D. Sin1,2

1Centre for Heart Lung Innovation, University of British Columbia, Vancouver, BC, Canada

2 Division of Respiratory Medicine, Faculty of Medicine, University of British Columbia, Vancouver, BC, Canada

3 Faculty of Medicine and Health, University of Sydney, Sydney, New South Wales, Australia

4 Institut universitaire de cardiologie et de pneumologie de Québec - Université Laval, Québec City, QC, Canada

5 University of Groningen, University Medical Centre Groningen, Department of Pathology and Medical Biology, Groningen, The Netherlands

6 University of Groningen, University Medical Center Groningen, Department of Pulmonary Diseases, Groningen, The Netherlands

7 Merck Research Laboratories, Genetics and Pharmacogenomics, Boston, Massachusetts, United States of America

8 Department of Genetics and Genomic Sciences and Icahn Institute for Data Science and Genomic Technology, Icahn School of Medicine at Mount Sinai, New York, NY, United States of America

**Corresponding author:** Ana I. Hernández Cordero, PhD

**Email:** Ana.Hernandez@ubc.hli.ca

**Address:** Centre for Heart Lung Innovation, Room 164,

1081 Burrard Street, St. Paul's Hospital, Vancouver, BC V6Z 1Y6

**Supplementary Table S1: Genes associated to COVID-19 through colocalization.**

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| Dataset | COVID-19 phenotype**‡** | Gene Symbol | Location† | PP.H4 |
| Lung eQTL (Lung tissue) | Susceptibility to COVID-19 | *WNK1* | 12p13.33 | 0.858 |
| *DYNC1LI1* | 3p22.3 | 0.839 |
| *IFNAR2* | 21q22.11 | 0.818 |
| Severe COVID-19 | ***SLC6A20*** | 3p21.31 | 0.987 |
| *KCNQ1-AS1* | 11p15.4 | 0.985 |
| ***ABO*** | 9q34.2 | 0.980 |
| *FOXP4-AS1* |  | 0.977 |
| *FLJ34503* |  | 0.976 |
| *IFNAR2* | 21q22.11 | 0.972 |
| *LOC103611081* |  | 0.970 |
| *ATP11A* | 13q34 | 0.935 |
| *RGS6* | 14q24.2 | 0.927 |
| *CHCHD4* | 3p25.1 | 0.920 |
| *IL10RB* | 21q22.11 | 0.917 |
| *DDX60L* | 4q32.3 | 0.887 |
| ***LZTFL1*** | 3p21.31 | 0.852 |
| *ADD2* | 2p13.3 | 0.837 |
| eQTLGEN(Blood tissue) | Susceptibility to COVID-19 | *RNF24* | 20p13 | 0.968 |
| *ITGAD* | 16p11.2 | 0.949 |
| *NIPAL2* | 8q22.2 | 0.914 |
| *DCUN1D1* | 3q27.1 | 0.878 |
| *SRC* | 20q11.23 | 0.873 |
| *PLA2G15* | 16q22.1 | 0.868 |
| *IFNAR2* | 21q22.11 | 0.839 |
| *RP5-1085F17.3* | 20q11.21 | 0.804 |
| Severe COVID-19 | *HNRNPU-AS1* | 1q44 | 0.974 |
| ***ABO*** | 9q34.2 | 0.971 |
| *ATP11A* | 13q34 | 0.966 |
| *IFNAR2* | 21q22.11 | 0.957 |
| *CTD-2555A7.3* | 16q24.3 | 0.939 |
| *GAS6* | 13q34 | 0.935 |
| *NDEL1* | 17p13.1 | 0.913 |
| *C7orf43* | 7q22.1 | 0.910 |
| *AF127936.7* | 21q11.2 | 0.880 |
| *CPOX* | 3q12.1 | 0.860 |
| *AC093901.1* | 2q14.2 | 0.857 |
| *OR52K3P* | 11p15.4 | 0.847 |
| *TRIM5* | 11p15.4 | 0.846 |
| *FRS2* | 12q15 | 0.845 |
| *PFKFB3* | 10p15.1 | 0.844 |
| *SRC* | 20q11.23 | 0.830 |
| *RP11-250B2.3* | 6q14.1 | 0.821 |
| *DOC2GP* | 11q13.2 | 0.808 |

†Cytogenetic location. **‡** Susceptibility to COVID-19 defined as a positive COVID-19 diagnosis versus the general population and severe COVID-19 defined as hospitalization for COVID-19 versus the general population. Bolded genes’ symbol represents those genes in genome-significant COVID-19 loci (PGWAS < 5 × 10-08). Underlined genes’ symbol represents those in suggestive COVID-19 loci (PGWAS < 5 × 10-05).

**Supplementary Table S2: Genes associated to COVID-19 through Summary-based Mendelian Randomization.**

|  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- |
| Dataset | COVID-19 phenotype**‡** | Gene Symbol | Location† | beta | se | PSMR | PHEIDI |
| Lung eQTL(Lung tissue) | Susceptibility to COVID-19 | ***SLC6A20*** | 3p21.31 | 0.28 | 0.06 | 3.50 × 10-07 | 0.36 |
| *ATP5O* | 21q22.11 | 1.44 | 0.39 | 2.13 × 10-04 | 0.45 |
| *IFNAR2* | 21q22.11 | -0.65 | 0.19 | 4.95 × 10-04 | 0.37 |
| *OAS1* | 12q24.13 | -0.14 | 0.04 | 7.07 × 10-04 | 0.06 |
| *C10orf32* | 10q24.32 | -0.33 | 0.10 | 8.14 × 10-04 | 0.47 |
| *AS3MT* | 10q24.32 | -0.25 | 0.08 | 8.48 × 10-04 | 0.10 |
| *DYNC1LI1* | 3p22.3 | 1.17 | 0.35 | 9.44 × 10-04 | 0.39 |
| Severe COVID-19 | ***SLC6A20*** | 3p21.31 | 0.58 | 0.09 | 1.33 × 10-10 | 0.41 |
| *IFNAR2* | 21q22.11 | -1.33 | 0.30 | 1.04 × 10-05 | 0.13 |
| eQTLGEN(Blood tissue) | Susceptibility to COVID-19 | *RNF24* | 20p13 | 0.42 | 0.11 | 8.52 × 10-05 | 0.73 |
| *ITGAD* | 16p11.2 | 0.29 | 0.07 | 9.69 × 10-05 | 0.15 |
| *NIPAL2* | 8q22.2 | -0.19 | 0.05 | 2.96 × 10-04 | 0.16 |
| *COX20* | 1q44 | 0.27 | 0.08 | 3.72 × 10-04 | 0.11 |
| *RP5-1085F17.3* | 20q11.21 | 0.21 | 0.06 | 5.15 × 10-04 | 0.61 |
| *OAS1* | 12q24.13 | -0.12 | 0.03 | 6.42 × 10-04 | 0.16 |
| *C10orf32* | 10q24.32 | -0.12 | 0.04 | 6.64 × 10-04 | 0.63 |
| *ESPNL* | 2q37.3 | 0.51 | 0.15 | 7.00 × 10-04 | 0.48 |
| *EXOSC6* | 16q22.1 | -0.12 | 0.04 | 9.47 × 10-04 | 0.70 |
| *ATP8B4* | 15q21.2 | -0.16 | 0.05 | 9.95 × 10-04 | 0.26 |
| Severe COVID-19 | *CTD-2555A7.3* | 16q24.3 | 0.51 | 0.14 | 2.39 × 10-04 | 0.65 |
| *GAS6* | 13q34 | -0.74 | 0.20 | 2.43 × 10-04 | 0.56 |
| *ATP11A* | 13q34 | -1.76 | 0.49 | 2.95 × 10-04 | 0.08 |
| *NDEL1* | 17p13.1 | -0.92 | 0.26 | 3.63 × 10-04 | 0.37 |
| *CEP120* | 5q23.2 | 1.29 | 0.36 | 4.09 × 10-04 | 0.47 |
| *CPOX* | 3q12.1 | -0.74 | 0.21 | 4.23 × 10-04 | 0.25 |
| *OR52K3P* | 11p15.4 | 0.14 | 0.04 | 4.51 × 10-04 | 0.58 |
| *AC093901.1* | 2q14.2 | 0.66 | 0.19 | 4.65 × 10-04 | 0.51 |
| *TRIM5* | 11p15.4 | -0.34 | 0.10 | 6.42 × 10-04 | 0.32 |
| *DOC2GP* | 11q13.2 | -0.13 | 0.04 | 6.55 × 10-04 | 0.16 |
| *OR52K2* | 11p15.4 | 0.39 | 0.12 | 8.58 × 10-04 | 0.40 |
| *LAYN* | 11q23.1 | -1.25 | 0.38 | 9.98 × 10-04 | 0.36 |

†Cytogenetic location. **‡** Susceptibility to COVID-19 defined as a positive COVID-19 diagnosis versus the general population and severe COVID-19 defined as hospitalization for COVID-19 versus the general population. Bolded genes’ symbols represent those genes in genome-significant COVID-19 loci (PGWAS < 5 × 10-08). Underlined genes’ symbols represent those in suggestive COVID-19 loci (PGWAS < 5 × 10-05).

**Supplementary Table S3. COVID-19 phenotypes and ABO plasma protein colocalization.**

|  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- |
| COVID-19phenotype | Protein | Location† | rsID | Allele (Alt/Ref) | pQTL effect‡ | GWAS effect (PGWAS) | PPH4 |
| Susceptibility to COVID-19 | ABO | 9q34.2 | rs505922 | T/C | -1.3 | -0.096 (2.4 × 10-05) | 0.97 |
| Severe COVID-19 | -0.14 (4.4 × 10-05) | 0.96 |

†Cytogenetic location. ‡No nominal P could be obtained for the ABO protein quantitative trait locus (pQTL) because of the high significance of the locus (close to 0). Susceptibility to COVID-19 defined as a positive COVID-19 diagnosis versus the general population and severe COVID-19 defined as hospitalization for COVID-19 versus the general population. ‘Alt’ allele is the effect allele. ‘GWAS effect’ refers to the allelic effect estimated in the COVID-19 association analyses.

Supplementary Table S4. Inverse variance weighting mendelian randomization (IVW-MR) of ABO plasma protein and COVID-19.

|  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- |
| COVID-19 phenotype† | IVW-MR est | IVW-MR SE | IVW-MR P | PCochran’s Q test | PEgger Intercept |
| Susceptibility to COVID-19  | 0.07 | 0.02 | 1.39 × 10-05 | 0.99 | 0.97 |
| Severe COVID-19 | 0.11 | 0.03 | 2.21 × 10-05 | 0.96 | 0.93 |

**†** Susceptibility to COVID-19 defined as a positive COVID-19 diagnosis versus the general population and severe COVID-19 defined as hospitalization for COVID-19 versus the general population.